The investment will empower RDHL to develop a virtual diagnostic and care platform, expanding access to healthcare for underserved communities
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Pfizer Ltd. has reported total income of Rs. 604.70 crores during the period ended June 30, 2024
This acquisition enables MTD to open new, strategic markets
Max Healthcare Institute has reported total income of Rs. 1380.99 crores during the period ended December 31, 2023
Dr Jitendra Singh launches API Chapter of AFMC, Pune; inaugurates the first annual conference of API-AFMS Continuing Medical Education (CME) on “Emerging trends in the practice of Medicine”
Good momentum in commercial CDMO business
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Subscribe To Our Newsletter & Stay Updated
